Myeloma

The FDA granted fast track designation to IBI3003 for patients with relapsed/refractory multiple myeloma after receiving four-plus lines of therapy.

CURE sat down with Dr. Surbhi Sidana to discuss this treatment combination and what its approval by the FDA would mean for patients.

Two people have transformed my journey from pain into possibility. In their presence, I find the strength to continue. Together, they've taught me that even in collapse and ill health, life can bloom again.

In patients with relapsed/refractory multiple myeloma, Tecvayli monotherapy is associated with a 71% reduction in the risk of disease progression or death.

Reach out to professionals, go to safe online sources, contact your local cancer support center. I hope these tools help you as they have helped me.

I reflect on a year of healing, family, and meaningful rituals while setting intentions for 2026 with vision, consistency and awakening.

Care partners for multiple myeloma patients emphasize that managing their own mental health is not a luxury, but a necessity for sustainable care.

Living with an incurable cancer that resists durable remission means holding hope and grief at the same time — existing between promising data and lived experience.

Oya Gilbert, diagnosed with multiple myeloma in 2017, advises patients to bring someone to appointments, ask questions and seek second opinions.

Treatment with Lynozyfic showed early responses and a manageable safety profile in patients with newly diagnosed multiple myeloma.

Following a multiple myeloma diagnosis, care partners describe an initial wave of fear and logistical stress.

This panel of multiple myeloma care partners shares diverse diagnostic journeys, offering vital insights for patients and caregivers.

KLN-1010 was associated with deep, ongoing minimal residual disease (MRD)–negative responses in multiple myeloma.

Tecvayli plus Darzalex Faspro improved overall and progression-free survival versus standard daratumumab regimens in relapsed/refractory multiple myeloma.

Dr. Robert Orlowski says a single-drug option in newly diagnosed myeloma may offer strong responses with fewer side effects and preserve future treatments.

KRd improved progression-free survival, deepened responses, and led to higher MRD negativity versus VRd in patients with newly diagnosed multiple myeloma.

Real-time text check-ins helped physicians identify issues sooner and support quality of life for patients with myeloma at ASH 2025.

In patients with R/R multiple myeloma, real-world Elrexfio was associated with shorter time until progression but higher rates of response than Tecvayli.

Dr. Amany Keruakous discussed how bispecific antibodies for multiple myeloma work by simultaneously targeting cancer cells and T cells.

I found purpose again after my myeloma diagnosis when I returned to teaching and shared my work, moments that reminded me I could still grow and reconnect.

I explain how the words caregiver and incurable shaped my wife’s cancer journey and why I believe more hopeful language better reflects our experience.

Panelists discuss how healthcare providers and patients should understand that talquetamab's unique side effects are temporary and resolve over time even while continuing treatment, emphasizing the drug's excellent efficacy and the importance of removing stigma around its manageable toxicity profile.

Panelists discuss how effective caregivers should join support groups, maintain detailed records of symptoms and medications, attend all appointments, stay informed about myeloma research, and serve as active advocates who can communicate with healthcare teams when patients cannot.

Panelists discuss how patients beginning talquetamab should maintain a positive attitude, prepare thoroughly with educational materials, and understand that while initial side effects can be challenging, they are temporary and manageable with proper preparation and support.